Cargando…
Role of Dok-1 and Dok-2 in Leukemia Suppression
Chronic myelogenous leukemia (CML) is characterized by the presence of the chimeric p210(bcr/abl) oncoprotein that shows elevated and constitutive protein tyrosine kinase activity relative to the normal c-abl tyrosine kinase. Although several p210(bcr/abl) substrates have been identified, their rele...
Autores principales: | Niki, Masaru, Di Cristofano, Antonio, Zhao, Mingming, Honda, Hiroaki, Hirai, Hisamaru, Van Aelst, Linda, Cordon-Cardo, Carlos, Pandolfi, Pier Paolo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211998/ https://www.ncbi.nlm.nih.gov/pubmed/15611295 http://dx.doi.org/10.1084/jem.20041306 |
Ejemplares similares
-
Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia
por: Yasuda, Tomoharu, et al.
Publicado: (2004) -
Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
por: Shinohara, Hisaaki, et al.
Publicado: (2005) -
P62(dok), a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210(bcr-abl)
por: Di Cristofano, Antonio, et al.
Publicado: (2001) -
DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
por: Berger, Alice H., et al.
Publicado: (2013) -
Phosphoinositide 3-Kinase–Dependent Membrane Recruitment of P62(dok) Is Essential for Its Negative Effect on Mitogen-Activated Protein (Map) Kinase Activation
por: Zhao, Mingming, et al.
Publicado: (2001)